[go: up one dir, main page]

WO2024159157A3 - Phospholipid analogs for hyperactivation of mammalian dendritic cells - Google Patents

Phospholipid analogs for hyperactivation of mammalian dendritic cells Download PDF

Info

Publication number
WO2024159157A3
WO2024159157A3 PCT/US2024/013204 US2024013204W WO2024159157A3 WO 2024159157 A3 WO2024159157 A3 WO 2024159157A3 US 2024013204 W US2024013204 W US 2024013204W WO 2024159157 A3 WO2024159157 A3 WO 2024159157A3
Authority
WO
WIPO (PCT)
Prior art keywords
dendritic cells
hyperactivation
mammalian dendritic
mammalian
phospholipid analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/013204
Other languages
French (fr)
Other versions
WO2024159157A2 (en
Inventor
Jonathan Chow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corner Therapeutics Inc
Original Assignee
Corner Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corner Therapeutics Inc filed Critical Corner Therapeutics Inc
Priority to EP24709926.0A priority Critical patent/EP4654955A2/en
Priority to CN202480007869.0A priority patent/CN120529901A/en
Publication of WO2024159157A2 publication Critical patent/WO2024159157A2/en
Publication of WO2024159157A3 publication Critical patent/WO2024159157A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present disclosure relates to phospholipid analog (PLA) compounds and uses thereof in hyperactivating mammalian dendritic cells, such as human dendritic cells or canine dendritic cells. The present disclosure also relates to compositions comprising a PLA and one or more of a pathogen recognition receptor agonist, an antigen, and mammalian dendritic cells, as well as methods for production and use of the compositions.
PCT/US2024/013204 2023-01-27 2024-01-26 Phospholipid analogs for hyperactivation of mammalian dendritic cells Ceased WO2024159157A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP24709926.0A EP4654955A2 (en) 2023-01-27 2024-01-26 Phospholipid analogs for hyperactivation of mammalian dendritic cells
CN202480007869.0A CN120529901A (en) 2023-01-27 2024-01-26 Phospholipid analogs for superactivation of mammalian dendritic cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363441702P 2023-01-27 2023-01-27
US63/441,702 2023-01-27

Publications (2)

Publication Number Publication Date
WO2024159157A2 WO2024159157A2 (en) 2024-08-02
WO2024159157A3 true WO2024159157A3 (en) 2024-09-06

Family

ID=90248991

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/013204 Ceased WO2024159157A2 (en) 2023-01-27 2024-01-26 Phospholipid analogs for hyperactivation of mammalian dendritic cells

Country Status (3)

Country Link
EP (1) EP4654955A2 (en)
CN (1) CN120529901A (en)
WO (1) WO2024159157A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015160986A2 (en) * 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016179475A1 (en) * 2015-05-07 2016-11-10 Baylor College Of Medicine Dendritic cell immunotherapy
WO2018147710A1 (en) * 2017-02-13 2018-08-16 단디바이오사이언스 주식회사 Nanoemulsion comprising imidazoquinoline-based material and use thereof
WO2022093770A1 (en) * 2020-10-27 2022-05-05 Memorial Sloan Kettering Cancer Center Combination therapy with pi3k-akt-mtor inhibitors and ferroptosis inducing agents to treat cancer
WO2022221827A2 (en) * 2021-04-12 2022-10-20 Corner Therapeutics, Inc. Hyperactivators of mammalian dendritic cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015160986A2 (en) * 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016179475A1 (en) * 2015-05-07 2016-11-10 Baylor College Of Medicine Dendritic cell immunotherapy
WO2018147710A1 (en) * 2017-02-13 2018-08-16 단디바이오사이언스 주식회사 Nanoemulsion comprising imidazoquinoline-based material and use thereof
WO2022093770A1 (en) * 2020-10-27 2022-05-05 Memorial Sloan Kettering Cancer Center Combination therapy with pi3k-akt-mtor inhibitors and ferroptosis inducing agents to treat cancer
WO2022221827A2 (en) * 2021-04-12 2022-10-20 Corner Therapeutics, Inc. Hyperactivators of mammalian dendritic cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUA ZHANG: "Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy", JOURNAL OF CONTROLLED RELEASE, vol. 330, 10 February 2021 (2021-02-10), AMSTERDAM, NL, pages 1080 - 1094, XP093164274, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2020.11.013 *
MOLLINEDO FAUSTINO ET AL: "In vitro and In vivo Selective Antitumor Activity of Edelfosine against Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Involving Lipid Rafts", CLINICAL CANCER RESEARCH, vol. 16, no. 7, 31 March 2010 (2010-03-31), US, pages 2046 - 2054, XP093187546, ISSN: 1078-0432, Retrieved from the Internet <URL:https://aacrjournals.org/clincancerres/article-pdf/16/7/2046/1994352/2046.pdf> DOI: 10.1158/1078-0432.CCR-09-2456 *
YANG PING ET AL: "Doxorubicin and Edelfosine Combo-Loaded Lipid-Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma", ONCOTARGETS AND THERAPY, vol. Volume 13, 1 August 2020 (2020-08-01), pages 8055 - 8067, XP093187544, ISSN: 1178-6930, Retrieved from the Internet <URL:https://www.dovepress.com/getfile.php?fileID=60553> DOI: 10.2147/OTT.S259428 *

Also Published As

Publication number Publication date
WO2024159157A2 (en) 2024-08-02
CN120529901A (en) 2025-08-22
EP4654955A2 (en) 2025-12-03

Similar Documents

Publication Publication Date Title
WO2022221827A3 (en) Hyperactivators of mammalian dendritic cells
EP4394032A3 (en) Methods for producing autologous t cells useful to treat cancers and compositions thereof
US20220002672A1 (en) Methods of producing t cell populations enriched for stable regulatory t-cells
WO2008058216A3 (en) Enriched stem cell and progenitor cell populations, and methods of producing and using such populations
Smyth et al. Continuous acquisition of MHC: peptide complexes by recipient cells contributes to the generation of anti-graft CD8+ T cell immunity
WO2005003168A3 (en) Methods for the production and cytotoxicity evaluation of kir2dl nk-receptor antibodies
EP3277675B1 (en) Heterocyclic modulators of lipid synthesis
BR112022002584A2 (en) YEAST CELL, METHOD FOR PRODUCING ONE OR MORE OLIGOSACCHARIDES, FERMENTATION COMPOSITION, METHOD FOR RECOVERING ONE OR MORE OLIGOSACCHARIDES, METHOD FOR GENETICALLY MODIFYING A YEAST CELL
BRPI0411585A (en) compounds, pharmaceutical composition and method of agglutinating opioid receptors in a patient in need thereof
Clark Perforin-a primary or auxiliary lytic mechanism
WO2024159157A3 (en) Phospholipid analogs for hyperactivation of mammalian dendritic cells
WO2024123975A3 (en) A t cell receptor recognizing an unmutated foxm1 epitope presented on hla-a*02:01
Hori et al. The ultrastructure of mitosis in Isochrysis galbana Parke (Prymnesiophyceae)
Wakikawa et al. Vitamin E enhances the immune functions of young but not old mice under restraint stress
US8710033B2 (en) Use of LPA for encouraging pregnancy, and fertility agent
BRPI0410646A (en) Acitretin pharmaceutical compositions and process for their preparation
NO20044608L (en) Process for preparing conjugated linoleic acid
SI2633034T1 (en) NFkB SIGNAL PATH-MANIPULATED DENDRITIC CELLS
AU2003224107A1 (en) Soluble composition containing sporopollenin and the use thereof
WO2023250433A3 (en) Engineered human t cells comprising a switchable chimeric antigen cell surface receptor and methods for generating them
EP4434541A3 (en) Antibodies specific to delta 1 chain of t cell receptor
US20180162909A1 (en) Conotoxin peptide k-cptx-btl03, preparation method therefor, and uses thereof
US20080182818A1 (en) Th1 CELL DIFFERENTIATION ACCELERATOR
MX2025003970A (en) Ether lipids for hyperactivation of mammalian dendritic cells
WO2024123794A3 (en) A t cell receptor recognizing a her2 mutation presented on hla-a*02:01 and methods of use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 202480007869.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 202480007869.0

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24709926

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2024709926

Country of ref document: EP